Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

Publisher： Karger

E-ISSN： 1421-9662|135|3|133-139

ISSN： 0001-5792

Source： Acta Haematologica, Vol.135, Iss.3, 2015-11, pp. : 133-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute

By  

Acta Haematologica, Vol. 128, Iss. 4, 2012-08 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 3, 2018-03 ,pp. : 332-338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Continuous Complete Hematological and Cytogenetic Remission with Molecular Minimal Residual Disease 9 Years after Discontinuation of Interferon-α in a Patient with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 109-112

Karger

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L.   Chen Lei   Guerin Annie   Macalalad Alexander R.   Liu Nathan   Kaminsky Michael   Ericson Solveig G.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite